- Home
- CUE vs VELO Comparison
CUE vs VELO Comparison
Compare CUE & VELO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- VELO
- Stock Information
- Founded
- CUE 2014
- VELO 2014
- Country
- CUE United States
- VELO United States
- Employees
- CUE N/A
- VELO N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- VELO Industrial Machinery/Components
- Sector
- CUE Health Care
- VELO Technology
- Exchange
- CUE Nasdaq
- VELO Nasdaq
- Market Cap
- CUE 61.1M
- VELO 63.7M
- IPO Year
- CUE 2018
- VELO N/A
- Fundamental
- Price
- CUE $0.70
- VELO $4.99
- Analyst Decision
- CUE Strong Buy
- VELO Strong Buy
- Analyst Count
- CUE 2
- VELO 1
- Target Price
- CUE $3.00
- VELO $6.00
- AVG Volume (30 Days)
- CUE 270.3K
- VELO 1.2M
- Earning Date
- CUE 11-12-2025
- VELO 11-26-2025
- Dividend Yield
- CUE N/A
- VELO N/A
- EPS Growth
- CUE N/A
- VELO N/A
- EPS
- CUE N/A
- VELO N/A
- Revenue
- CUE $8,286,000.00
- VELO $43,765,000.00
- Revenue This Year
- CUE N/A
- VELO $30.60
- Revenue Next Year
- CUE N/A
- VELO $57.71
- P/E Ratio
- CUE N/A
- VELO N/A
- Revenue Growth
- CUE N/A
- VELO N/A
- 52 Week Low
- CUE $0.54
- VELO $1.43
- 52 Week High
- CUE $1.99
- VELO $29.25
- Technical
- Relative Strength Index (RSI)
- CUE 38.97
- VELO N/A
- Support Level
- CUE $0.76
- VELO N/A
- Resistance Level
- CUE $0.81
- VELO N/A
- Average True Range (ATR)
- CUE 0.05
- VELO 0.00
- MACD
- CUE -0.01
- VELO 0.00
- Stochastic Oscillator
- CUE 10.92
- VELO 0.00
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About VELO Velo3D Inc. Common stock
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.